BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor
1 clinical trials · Condition
◉ Watch BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor
| Record | Firm | Date |
|---|---|---|
| Special Drug Use-results Surveillance of Tafinlar/Mekinist (NCT06262919) | Novartis Pharmaceuticals | 2024-02-09 |
Track BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor automatically
Every clearance here is in the API, with alerts when new ones post.